Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03344211 · ClinicalTrials.gov registry record · Phase 2

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

A Phase 2 study of Castration-Resistant Prostate Carcinoma and Stage IV Prostate Cancer, sponsored by University of Southern California.

Active
Registry status
Phase 2
Development phase
30
Enrollment target
3
Study locations

NCT03344211 is a Phase 2 study of Castration-Resistant Prostate Carcinoma and Stage IV Prostate Cancer that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 30 participants, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (61% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03344211, a Phase 2 study of Castration-Resistant Prostate Carcinoma and Stage IV Prostate Cancer, is active but no longer recruiting, sponsored by University of Southern California.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

This randomized phase II trial studies how well enzalutamide with or without radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Enzalutamide is an androgen receptor inhibitor that may slow down the growth of prostate cancer by blocking the action of the male hormone testosterone and other male hormones called androgens. Radiation therapy uses high energy alpha particles to kill tumor cells and shrink tumors. Enzalutamide with or without radium Ra 223 dichloride may work better in treating patients with castration-resistant prostate cancer.

Conditions Studied

Castration-Resistant Prostate Carcinoma Stage IV Prostate Cancer Prostate Carcinoma Metastatic in the Bone

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Enzalutamide
  • RADIATION Radium Ra 223 Dichloride

Study Locations (3)

California

  • City of Hope - Duarte
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-11-21
Est. Completion 2027-11-21
Phase Phase 2

Sponsor

University of Southern California

617 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03344211

The ClinicalTrials.gov registry entry for NCT03344211 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (61% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT03344211 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03344211 about?

NCT03344211 is a clinical study titled "Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer". This randomized phase II trial studies how well enzalutamide with or without radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Enzalutamide is an androgen receptor inhibitor that may slow down the growth of prostate c...

What is the current status of trial NCT03344211?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-11-21. Estimated completion is 2027-11-21.

What conditions does trial NCT03344211 study?

This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer, Prostate Carcinoma Metastatic in the Bone.

What interventions are being tested in trial NCT03344211?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Enzalutamide (DRUG), Radium Ra 223 Dichloride (RADIATION).

Who is sponsoring clinical trial NCT03344211?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03344211 being conducted?

This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-Resistant Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Castration-Resistant Prostate Carcinoma

All registered trials for this condition

Stage IV Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.